Therapeutic Advances in Diabetic Nephropathy

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic kidney disease (DKD) is the primary cause of end-stage kidney disease (ESKD) in the US.
• Established risk factor modifications include glycemic control, blood pressure management, and RAAS blockade.

Purpose of the Study:

• To review current and novel therapeutic strategies for managing diabetic kidney disease.
• To provide an overview of treatment options for delaying DKD progression.

Main Methods:

• Literature review of established and emerging treatments for diabetic kidney disease.
• Synthesis of evidence on risk factor modification and new drug classes.

Main Results:

• Traditional management involves blood glucose, blood pressure, and lipid control, alongside RAAS blockade.
• Novel therapies include SGLT2 inhibitors, endothelin antagonists, GLP-1 agonists, and MRAs.

Conclusions:

• Multiple therapeutic avenues exist to manage and potentially delay the progression of DKD.
• Emerging drug classes offer new hope for patients with diabetic kidney disease.